Triallate (CASRN 2303-17-5)
view QuickView

0195
Triallate;
CASRN 2303-17-5
Health assessment information on a chemical substance is included in IRIS
only after a comprehensive review of chronic toxicity data by U.S. EPA
health scientists from several Program Offices and the Office of Research
and Development. The summaries presented in Sections I and II represent
a consensus reached in the review process. Background information and
explanations of the methods used to derive the values given in IRIS are
provided in the Background Documents.
STATUS OF DATA FOR Triallate
File First On-Line 03/31/1987
Category (section) |
Status |
Last Revised |
---|---|---|
Oral RfD Assessment (I.A.) | on-line | 01/01/1992 |
Inhalation RfC Assessment (I.B.) | no data | |
Carcinogenicity Assessment (II.) | no data |
_I. Chronic Health Hazard Assessments for Noncarcinogenic Effects
_I.A. Reference Dose for Chronic Oral Exposure (RfD)
Substance Name — Triallate
CASRN — 2303-17-5
Last Revised — 01/01/1992
The oral Reference Dose (RfD) is based on the assumption that thresholds
exist for certain toxic effects such as cellular necrosis. It is expressed
in units of mg/kg-day. In general, the RfD is an estimate (with uncertainty
spanning perhaps an order of magnitude) of a daily exposure to the human
population (including sensitive subgroups) that is likely to be without
an appreciable risk of deleterious effects during a lifetime. Please refer
to the Background Document for an elaboration of these concepts. RfDs
can also be derived for the noncarcinogenic health effects of substances
that are also carcinogens. Therefore, it is essential to refer to other
sources of information concerning the carcinogenicity of this substance.
If the U.S. EPA has evaluated this substance for potential human carcinogenicity,
a summary of that evaluation will be contained in Section II of this file.
__I.A.1. Oral RfD Summary
Critical Effect |
Experimental Doses* |
UF |
MF |
RfD |
---|---|---|---|---|
Increased hemosiderin 2-Year Dog Feeding Monsanto, 1979 |
NOAEL: 1.275 mg/kg/day LOAEL: 4.25 mg/kg/day |
100
|
1
|
1.3E-2
mg/kg/day |
*Conversion Factors: see text
__I.A.2. Principal and Supporting Studies (Oral RfD)
Monsanto Company. 1979. MRID No. 00029455; HED Doc. No. 005525. Available
from EPA. Write to FOI, EPA, Washington, DC 20460.
Four beagle dogs/sex/group were fed 0, 1.5, 5 and 15 mg/kg triallate ad
libitum for 24 months. At the end of the study, animals were sacrificed and
necropsied. An increase in liver weight in the high-dose group of males and
mid-dose group of females was observed. An increase in hemosiderin
deposition, particularly in the spleen, was noted in all triallate-treated
groups, and an increase in serum alkaline phosphatase levels was observed in
the mid-dose and high-dose groups. The effect of increased hemosiderin
deposition at the low dose was slight to minimal; at higher doses there were
no effects related to the hematopoietic system. The amount of triallate in
the diets was calculated to be 1.275 mg/kg/day, 4.25\mg/kg/day, and 12.75
mg/kg/day as a result of dogs receiving, on the average, 85% of the targeted
doses in their diets.
__I.A.3. Uncertainty and Modifying Factors (Oral RfD)
UF — An uncertainty factor of 100 was used to account for inter- and
intraspecies differences.
MF — None
__I.A.4. Additional Studies/Comments (Oral RfD)
None
Data Considered for Establishing the RfD:
1) 2-Year Feeding - dog: Principal study - see previous description; core grade minimum
2) 2-Year Feeding - mouse: NOEL=20 ppm (3 mg/kg/day); LEL=60 ppm (9
mg/kg/day) (increased splenic hematopoiesis for males); core grade minimum
(Monsanto Co., 1983)
3) Chronic Feeding - hamster: NOEL=50 ppm (5 mg/kg/day); LEL=300 ppm (30
mg/kg/day) (decreased triglycerides in males); core grade supplementary
(urinalyses and clotting measurements were reported) (Monsanto Co., 1984a)
4) 2-Generation Reproduction - rat: Tentative NOEL=150 ppm (7.5 mg/kg/day);
Tentative LEL=600 ppm (30 mg/kg/day) (head bobbing and circling in pregnant
females, reduced mean pup weight at birth); core grade minimum (Monsanto Co.,
1984b)
5) Teratology - rat: Maternal and Fetotoxic NOEL=30 mg/kg/day; Maternal and
Fetotoxic LEL=90 mg/kg/day (reduced weight and reduced ossification); core
grade minimum (Monsanto Co., 1982a)
6) Teratology - rabbit: Fetotoxic NOEL=5 mg/kg/day; Fetotoxic LEL=15
mg/kg/day (unossified sternabrae and an increase in skeletal malformations);
core grade minimum (Monsanto Co., 1982b)
Data Gap(s): Chronic Rat Feeding Study
__I.A.5. Confidence in the Oral RfD
Study — Medium
Database — High
RfD — High
The critical study is of adequate quality and is given a medium confidence rating. The database on chronic toxicity is supportive; therefore, confidence in the database can be considered high to medium. Confidence in the RfD can also be considered high to medium.
__I.A.6. EPA Documentation and Review of the Oral RfD
Pesticide Registration Files
Agency Work Group Review — 12/16/1986
Verification Date — 12/16/1986
__I.A.7. EPA Contacts (Oral RfD)
Please contact the IRIS Hotline for all questions concerning this assessment or IRIS, in general, at (202)566-1676 (phone), (202)566-1749 (FAX) or hotline.iris@epa.gov (internet address).
_I.B. Reference Concentration for Chronic Inhalation Exposure (RfC)
Substance Name — Triallate
CASRN — 2303-17-5
Not available at this time.
_II. Carcinogenicity Assessment for Lifetime Exposure
Substance Name — Triallate
CASRN — 2303-17-5
This substance/agent has not undergone a complete evaluation and determination under US EPA's IRIS program for evidence of human carcinogenic potential.
_III.
[reserved]
_IV. [reserved]
_V. [reserved]
_VI. Bibliography
Substance Name — Triallate
CASRN — 2303-17-5
Last Revised — 01/01/1992
_VI.A. Oral RfD References
Monsanto Company. 1979. MRID No. 00029455; HED Doc. No. 005525. Available
from EPA. Write to FOI, EPA, Washington, DC 20460.
Monsanto Company. 1982a. MRID No. 00114260, 92187021; HED Doc. No. 002996,
003651. Available from EPA. Write to FOI, EPA, Washington, DC 20460.
Monsanto Company. 1982b. MRID No. 00114261, 92187022; HED Doc. No. 002996.
Available from EPA. Write to FOI, EPA, Washington, DC 20460.
Monsanto Company. 1983. MRID No. 00132859, 92187020; HED Doc. No. 004942,
006996. Available from EPA. Write to FOI, EPA, Washington, DC 20460.
Monsanto Company. 1984a. MRID No. 00132881, 00151790, 00159797, 00163574,
92187052; HED Doc. No. 006996, 007279. Available from EPA. Write to FOI,
EPA, Washington, DC 20460.
Monsanto Company. 1984b. MRID No. 00132880, 00144308, 92187023; HED Doc. No.
004942, 005735. Available from EPA. Write to FOI, EPA, Washington, DC
20460.
_VI.B. Inhalation RfC References
None
_VI.C. Carcinogenicity Assessment References
None
_VII. Revision History
Substance Name — Triallate
CASRN — 2303-17-5
Date |
Section |
Description |
---|---|---|
03/01/1988 | I.A.5. | Confidence levels revised |
08/01/1990 | I.A.1. | RfD exponent corrected |
01/01/1992 | I.A.4. | Citations added |
01/01/1992 | IV. | Regulatory Action section on-line |
01/01/1992 | VI. | Bibliography on-line |
04/01/1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
02/22/2001 | I.A., II. | This chemical is being reassessed under the IRIS Program. |
02/09/2004 | I.A., II. | This chemical is no longer being reassessed under the IRIS Program. See Federal Register February 9, 2004 (Volume 69, Number 26). |
_VIII. Synonyms
Substance Name — Triallate
CASRN — 2303-17-5
Last Revised — 03/31/1987
- 2303-17-5
- AVADEX BW
- CARBAMIC ACID, DIISOPROPYLTHIO-, S-(2,3,3-TRICHLOROALLYL) ESTER
- CP 23426
- DIISOPROPYLTRICHLOROALLYLTHIOCARBAMATE
- DIPTHAL
- FAR-GO
- N-DIISOPROPYLTHIOCARBAMIC ACID S-2,3,3-TRICHLORO-2-PROPENYL ESTER
- N,N-DIISOPROPYL-2,3,3-TRICHLORALLYL-THIOLCARBAMAT
- 2-PROPENE-1-THIOL, 2,3,3-TRICHLORO-, DIISOPROPYLCARBAMATE
- S-2,3,3-TRICHLOROALLYL N,N-DIISOPROPYLTHIOCARBAMATE
- THIOCARBAMIC ACID, N-DIISOPROPYL-, S-2,3,3-TRICHLOROALLYL ESTER
- TRIALLAT
- Triallate
- 2,3,3-TRICHLORALLYL-N,N-(DIISOPROPYL)-THIOCARBAMAT
- 2,3,3-TRICHLOROALLYL DIISOPROPYLTHIOCARBAMATE